



Business Results First Nine Months of the Fiscal Year Ending March 31, 2024

February 9, 2024
Sysmex Corporation

Together for a better
healthcare journey

Index

- 1. Executive Summary**
- 2. Business Results, First Nine Months of the Fiscal Year Ending March 31, 2024**
- 3. Future Growth Initiatives**
- 4. Financial Forecast for the Fiscal Year Ending March 31, 2024**
(Appendix)
 - Quarterly Operating Performance**
 - Topics**
 - XR™-Series (Hematology Field) Launch Schedule**

- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.
- In the fiscal year ended March 31, 2022, the Sysmex Group changed its method of recognizing the costs of configuration or customization services in cloud computing contracts as an expense when these services are received.
- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

1. Executive Summary

Q3 Performance

Net sales reached a record high. (¥326.5 billion, 109.3% year on year)

- Sales hit record highs in the Americas, China, and AP.
- Sales in EMEA were flat year on year, covering such negative impacts as falling demand for COVID-19 tests and the situation in Russia.
- In Japan, as well, sales remained on a par with the previous year as we covered the decline in demand for COVID-19 tests.
Note: In China, the impact of local anti-corruption campaigns was slight, and sales rose by double digits.

Operating profit was flat. (¥54.2 billion, 99.7% year on year)

- Gross profit increased, owing to the rise in net sales and an improved cost of sales ratio.
- SG&A expenses rose owing to higher labor costs to reinforce human capital, the start of depreciation on expenses related to digitalization, and yen depreciation.
- Operating profit was flat, due in part to the impact of other operating income (expenses)*. * Fire indemnification payment (¥1.9 billion) received in the previous year

Net sales, the cost of sales ratio, and operating profit were generally in line with expectations.


- Business was steady in all regions.
- In the Americas, we experienced shipment delays. This caused a shift in the sales period to Q4 for some products. With the exception of this factor, performance was generally in line with plan.

2. Business Results, First Nine Months of the Fiscal Year Ending March 31, 2024

Financial Highlights (Year on Year)



(Billions of yen)	First nine months of fiscal year ending March 31, 2024		First nine months of fiscal year ended March 31, 2023		YoY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	326.5	100%	298.7	100%	109.3%
Cost of sales	154.7	47.4%	143.8	48.2%	107.6%
SG&A expenses	95.8	29.4%	81.5	27.3%	117.5%
R&D expenses	23.2	7.1%	22.0	7.4%	105.2%
Other income (expenses)	1.5	0.5%	3.1	1.0%	48.3%
Operating profit	54.2	16.6%	54.3	18.2%	99.7%
Profit attributable to owners of the parent	34.4	10.6%	35.1	11.8%	98.0%



✓ **Net sales:** Sales were up by double digits in overseas regions, pushing up overall net sales to a record high.

✓ **Operating profit:** Gross profit rose due to improved cost of sales, but operating profit was flat due to an increase in SG&A expenses and a decrease in other income.

– **Forex impact** Net sales: + ¥10.80 billion SG&A expenses: +¥3.59 billion Operating profit: +¥6.66 billion

– **At forex rates prevailing one year earlier:** Net sales: +5.7% SG&A expenses: +13.1% Operating profit: -12.6%


✓ **Profit attributable to owners of the parent:** Profit was down due to an increase in taxes

Note: Foreign exchange loss (gain): Gain of ¥0.19 billion (a year-on-year increase of ¥0.96 billion)

	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023
1 USD	¥143.3	¥136.5
1 EUR	¥155.3	¥140.6
1 CNY	¥20.0	¥19.9

Breakdown of Net Sales (By Business and Field)

Net Sales by Business and Field



In the hematology field, sales grew mainly in emerging markets and in China, where we promoted a shift to local production. Sales also increased in the urinalysis and hemostasis fields. In the immunochemistry field, sales were down due to the impact of falling demand for COVID-19 tests, although sales in China increased.

(Billions of yen)	First nine months of fiscal year ending March 31, 2024		YoY (Previous year = 100%)	
	Results	Ratio	Yen basis	Excluding FX impact
Net sales	326.5	100.0%	109.3%	105.7%
Hematology	195.3	59.8%	111.3%	107.2%
FCM	2.4	0.7%	137.7%	132.7%
Urinalysis	27.9	8.6%	116.3%	112.1%
Hemostasis	50.8	15.6%	103.8%	102.3%
Immunochemistry	16.5	5.1%	98.7%	98.2%
Clinical chemistry	2.4	0.8%	94.0%	92.2%
Life science	15.1	4.6%	101.2%	95.3%
Others	13.9	4.3%	111.8%	105.7%
Diagnostics business	324.5	99.4%	109.3%	105.6%
Medical robotics business	2.0	0.6%	117.6%	117.6%

Tests related to COVID-19

(Included in life science, immunochemistry and others)
Q1–Q3 FY03/2024: ¥2.03 billion (sales in Japan only)


(Reference) Q1–Q3 FY03/2023: ¥5.15 billion
(¥4.67 billion in Japan, ¥0.47 billion overseas)

Breakdown of Net Sales (By Destination and Product Type)

Double-digit sales increases in China and AP drove the Group's growth.

(Billions of yen)	First nine months of fiscal year ending March 31, 2024		YoY (Previous year = 100%)	
	Results	Ratio	Yen basis	Local currency basis
Net sales	326.5	100.0%	109.3%	105.7%*
Americas	85.3	26.1%	110.5%	105.4%
EMEA	92.8	28.4%	109.7%	99.3%
China	73.4	22.5%	111.2%	110.8%
AP	31.6	9.7%	116.8%	113.1%*
Japan	43.3	13.3%	99.0%	-
Instruments	68.6	21.0%	106.6%	102.2%*
Reagents	199.7	61.2%	109.6%	106.4%*
Services	44.7	13.7%	112.1%	107.4%*
Other	13.3	4.1%	110.5%	107.8%*


*Year-on-year increase on a yen basis, excluding the impact of exchange rate fluctuations



Major Reasons for Changes, by Destination

Note: Comments below refer to sales on a local currency basis.

Americas	<ul style="list-style-type: none"> Sales rose. We received a record number of orders, and performance was favorable in the hematology and immunochemistry fields.
EMEA	<ul style="list-style-type: none"> Sales for the region were flat, as a shift to direct sales boosted sales in Saudi Arabia and Spain, overcoming extraordinary factors (Russia, COVID-19). Excluding extraordinary factors, sales would have risen by 5.4%.
China	<ul style="list-style-type: none"> Sales rose by double digits. The number of tests rebounded, and a shift to local production resulted in substantial growth in the hematology field. Also, sales of urinalysis and immunochemistry reagents expanded.
AP	<ul style="list-style-type: none"> Sales rose by double digits. Performance in each country was favorable, and sales of instruments and reagents rose in all fields.
Japan	<ul style="list-style-type: none"> Sales were flat. Favorable instrument sales pushed up sales in the hematology, urinalysis, and hemostasis fields. However, demand for tests related to COVID-19 decreased.




Information by Destination (Americas)



(Million USD)	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	595.4	565.1	105.4%	110.5%
Instruments	151.4	144.2	105.0%	109.9%
Reagents	284.2	266.5	106.7%	111.8%
Services, others	159.7	154.4	103.5%	108.6%

We experienced some shipment delays in Q4, but sales in the Americas increased due to growth in the hematology and urinalysis fields. Absent this shift in the sales period (USD11 million), sales in the Americas would have been up 7.5% year on year.



● Instruments

- ✓ Sales in the urinalysis field rose in Brazil and the United States. Sales also rose in the hematology field in Brazil, pushing up instrument sales for the region.

● Reagents


- ✓ Sales rose, owing to expansion of the installed instrument base in the hematology and urinalysis fields in North, Central and South America.
- ✓ Reagent sales of a lab-developed test for amyloid β in the blood for a large commercial lab (Labcorp) also increased.

Information by Destination (EMEA)

(Million EUR)	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	597.5	601.9	99.3%	109.7%
Instruments	142.5	156.5	91.1%	100.6%
Reagents	359.4	349.5	102.9%	113.7%
Services, others	95.4	95.9	99.5%	109.9%

Sales for the region remained on a par with the previous year, as a shift to direct sales boosted sales in Saudi Arabia and Spain, and other countries contributed, overcoming a sharp downturn in sales in Russia.

Note: Excluding extraordinary factors (Russia, COVID-19), sales would have been up by 5.4% on a local currency basis. The impact from Russia continued to Q3 and will not affect performance in Q4.



● Instruments

✓ A shift to direct sales pushed up sales in Saudi Arabia, Spain and other countries. Even so, instrument sales were down due to comparison with a large tender won in Italy in the previous year.

● Reagents

✓ Sales increased in the hematology field, helped by the transition to direct sales in Saudi Arabia and Spain, leading to an increase in reagent sales.

Information by Destination (China)

(Million CNY)	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	3,668.5	3,311.8	110.8%	111.2%
Instruments	496.7	484.3	102.6%	102.5%
Reagents	2,714.2	2,430.8	111.7%	112.2%
Services, others	457.5	396.8	115.2%	116.1%



- Owing to a recovery in the number of tests and the expansion of local production, sales of instruments and reagents both increased, despite the impact of government procurement policies.
- Sales have recovered to pre-pandemic levels.
- We obtained regulatory approval for local production of three models.

● Instruments

- ✓ Owing to an increase in local production, sales in the hematology field rose by double digits, pushing up overall sales.
- ✓ Sales adjusted for the launch of products manufactured locally, causing a slowdown in the urinalysis field, but we anticipate a recovery in Q4.

● Reagents

- ✓ Sales rose due to double-digit sales increases in the hematology, urinalysis, and immunochemistry fields.



Response to the Chinese Market

External environmental impacts have largely run their course, and the transition to local production of instruments is progressing smoothly. We will expand our business by promoting measures tailored to the “new normal” environment.

(This slide was shown in the financial results for the first six months of the fiscal year ending March 31, 2024)

Note: Progresses in Q3 are in green.

- ✓ Promoting the transition to local production of instruments (applied to six instruments already, **one model has been launched, and two models have received regulatory approval**)

Government procurement policies

Chinese Market Trends

- Growing healthcare demand due to aging population
- Per capita national health care expenditure to reach the level of developed countries (currently, one-seventh that of Japan)
- Increased demand due to upgraded at approximately 2,000 Tier 2 hospitals (1,000-prefecture process)
- Economic stagnation as business activity slows (Negligible impact on the healthcare market)

Centralized purchasing

- ✓ Shift to direct sales and services
- ✓ Introduced lower-cost reagents into the market
- ✓ Won a tender for immunochemistry reagents in Anhui Province

Rise of competitors

- ✓ Develop products that are competitive and unique

Anti-corruption movement


- ✓ Although some tenders have been delayed, we expect the impact on our sales to be negligible. **No major impact in Q3.**
- ✓ A healthier market environment is advantageous for our company

Schedule for Moving Production to China

We have received regulatory approval on three new instruments, and we will commence production with a view to launching them this fiscal year.

Transition to local production concluded (six models)


Transition to local production planned (four models)



Information by Destination (AP)

(Billions of yen)	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023	YoY (Previous period = 100%) Yen basis
Net sales	31.6	27.0	116.8% (113.1%)
Instruments	7.1	5.9	121.0%
Reagents	21.0	18.8	111.4%
Services, others	3.4	2.2	150.0%

Note: Figures in parentheses exclude the impact of exchange rate fluctuations.



Sales rose by double digits in all fields, buoyed by strong ongoing demand for investment in healthcare infrastructure and an increase in the installed instrument base.

● Instruments

- ✓ Sales rose by double digits, pushed up by higher sales in the hematology field across all regions, as well as by higher sales in the urinalysis and hemostasis fields in Thailand and India, and by substantially higher sales in the immunochemistry field in Indonesia and South Korea.


● Reagents

- ✓ Owing to expansion of the installed instrument base, sales rose favorable, centered on the hematology field in India, Australia and South Korea.
- ✓ Performance was favorable in the immunochemistry field, and increases in all fields led to double-digit sales growth.

Information by Destination (Japan)

(Billions of yen)	First nine months of fiscal year ending March 31, 2024	First nine months of fiscal year ended March 31, 2023	YoY (Previous period = 100%) Yen basis
Net sales	43.3	43.7	99.0% (105.6%)
Diagnostics business	41.3	42.0	98.2% (105.1%)
Instruments	6.5	5.7	113.6%
Reagents	27.7	29.3	94.5% (104.1%)
Services, others	7.0	6.9	101.4%
Medical robotics business	2.0	1.7	117.6%

Note: Figures in parentheses exclude the impact of COVID-19.



Favorable sales of the XR™-Series, as well as the CN-Series in the hemostasis field, led to double-digit growth in instrument sales. Nevertheless, sales for the region declined as a result of falling demand for testing related to COVID-19.

Diagnostics business

● Instruments

- ✓ Instrument sales increased by double digits, owing to the XR-Series in the hematology field, the CN-Series in the hemostasis field, and the introduction of new products for small and medium-sized facilities in the urinalysis field.

● Reagents

- ✓ Despite expanded adoption of our thrombus parameters in the hemostasis field, reagent sales declined, due to a fall in demand related to testing for COVID-19 (-¥2.64billion).

Medical robotics business


- ✓ Five units were installed in Q3, bringing the total so far this fiscal year to nine*.
- ✓ Since the start of sales, 44 units have been installed.
- ✓ 3,314 cases (as of December 31, 2023)

*Contract details differ, depending on the sales scheme and the amount and timing to book as sales are different, so the number of units installed does not align with sales results.

Breakdown of Operating Profit

Operating Profit

(Billions of yen)



Note: Figures and comments below exclude the impact of exchange rates.

- Increased gross profit on higher sales: ¥8.80 billion positive impact
 - Impact of change in the cost of sales ratio: ¥2.20 billion (0.7pt deterioration)
 - ✓ Positive factor: Easing of sharply higher shipping costs: 0.3pt
 - ✓ Negative factors: Service costs: 0.6pt; deterioration in cost of sales of products: 0.4pt deterioration
 - Higher SG&A expenses: ¥8.09 billion
 - ✓ Labor costs: Mainly due to an increase in personnel stemming from a shift to direct sales, as well as higher labor costs due to inflation: Approx. ¥6.0 billion
 - ✓ Expenses: Increase stemming from an expansion in scale and the reinforcement of sales promotion activities: Approximately ¥2.0 billion
 - Higher digitalization-related expenses: ¥2.6 billion
 - Higher R&D expenses: ¥1.15 billion
 - ✓ Ongoing investments in product development and higher costs related to regulatory affairs
 - Changes in other operating income (expenses): ¥1.57 billion
 - ✓ Changes due to fire indemnification in the previous year
-
- FX impact: ¥6.66 billion positive impact


3

Future Growth Initiatives

Emerging Market Strategies / Reinforcement of Existing Businesses /
New Business Expansion


Emerging Market Strategies

Performance is up sharply, particularly in India, Brazil, and Saudi Arabia, and year-to-date performance as of Q3 is already at the previous year-end level. We will actively invest and capture opportunities in regions where significant market growth is expected due to economic expansion and increases in healthcare quality.



■ Global South


Sales in India



Sales in Brazil



Sales in Saudi Arabia



Reinforcement of Existing Businesses (Immunochemistry, Hemostasis, Life Science)



Immunochemistry

Rapidly accelerate global expansion by leveraging existing assets and forming new alliances

- ✓ In the United States, we are experiencing favorable sales of reagents to test for amyloid β in the blood (for LDT), and we are promoting collaboration with a large commercial lab (Labcorp)
- ✓ Accelerate the development of new testing parameters and the global rollout based on basic agreement on business collaboration with Fujirebio Holdings, Inc.

Hemostasis

Aiming to be the No. 1 manufacturer with an overwhelming global market share

- ✓ Begin sales in the United States and Europe under the global OEM agreement with Siemens Healthcare Diagnostics Inc. (fiscal year ending March 31, 2025)

Life Science

Pivot the business

● Short-term: Increase profitability

- ✓ OSNA™
- ✓ FISH (Oxford Gene Technology)
- ✓ PCR (cancer, infectious disease, etc.)

● Mid/long-term: Become profitable

- ✓ Liquid biopsy (Sysmex Inostics, Inc.)
- ✓ Sequence

Global expansion of stable revenue source businesses

Selection and focus

- ✓ Move from the lab assay business to the testing kit business
- ✓ Move from BEAMing to Plasma-Safe-SeqS (PSS)

Dramatically reduce testing costs

- ✓ Develop of a new genetic testing system in collaboration with Hitachi High-Tech Corporation and others

New Business Expansion

Regenerative and Cellular Medicine

- **In December 2023, made Megakaryon Corporation into a consolidated subsidiary.**
 - ✓ Accelerating efforts toward the early commercialization of human iPS cell-derived platelet preparations
 - ✓ Application as a raw material for the standard substances used in the quality control of our testing instruments



- **We will apply the analysis technology we have cultivated in the field of hematology to the commercialization of human iPS cell-derived platelet preparations, helping to reduce risks at the time of platelet transfusion.**

- ✓ Reduction in allergic reactions and other side effects
- ✓ Reduced incidence of platelet transfusion refractoriness*

*A condition in which repeated transfusions produce antibodies that the effectiveness of the transfusion is lost.




Realization of safe medical care
Higher patient quality of life

Medical Robotics Business

- ✓ Launched an upgraded model in July 2023
- ✓ Surgeries performed to date exceeded 3,000 as of December 31, 2023, indicating steady progress
- ✓ Units installed to date: 44 (nine more this fiscal period)
- ✓ Number of certified physicians: 570 (up by 283 this fiscal period)
- ✓ **In November 2023, filed application for use in respiratory surgery**
- ✓ In September 2023, **received marketing approval** from Singapore's Health Sciences Authority

Surgeries Performed in Japan



4. Financial Forecast for the Fiscal Year Ending March 31, 2024

Initiatives for Achieving Full-Year Targets



(Updated from the financial results for the first six months of the fiscal year ending March 31, 2024)

- **Increase sales**
 - ✓ The XR-Series in Japan, EMEA, and AP; and the XN-Series and BT-50 in China and the Americas
 - ✓ Transition to local production in China (high/mid/low-end instruments in the hematology field, urine chemistry analyzers, hemostasis analyzers) and expand sales of new testing parameters in the immunochemistry field
 - ✓ Increase instrument sales to Siemens Healthcare Diagnostics Inc. (begin supplying based on global OEM agreement)
- **Reduce the cost of sales ratio**
 - ✓ Expand sales of reagents using in-house raw materials
 - ✓ Pass on prices in some regions and on some items
 - ✓ Lower costs of materials such as semiconductors, which had soared
- **Reorganize businesses and R&D to utilize SG&A expenses more efficiently**
 - ✓ Review priorities
 - ✓ Achieve cost reduction through efficient resource allocation

Financial Forecast for the Fiscal Year Ending March 31, 2024

No changes to our full-year forecast subsequent to the November 2023 revisions

(Billions of yen)	First nine months of fiscal year ending March 31, 2024 (April–December)		Fiscal year ending March 31, 2024 (April–March)		
	Results	Ratio	Revised forecast	Ratio	YoY (Previous period = 100%)
Net sales	326.5	100.0%	460.0	100.0%	112.1%
Cost of sales	154.7	47.4%	217.5	47.3%	111.9%
SG&A expenses	95.8	29.4%	125.5	27.3%	111.7%
R&D expenses	23.2	7.1%	34.5	7.5%	111.1%
Other income (expenses)	1.5	0.5%	0.5	0.1%	48.6%
Operating profit	54.2	16.6%	83.0	18.0%	112.7%

Planned investment

Capital expenditure: **¥47.8** billion

Depreciation and amortization: **¥35.0** billion

● Assumed Exchange Rates

	Full year (Announced May 2023)	Full year (Revised Nov. 2023)	Second half (Revised Nov. 2023)	Fiscal year ended March 31, 2023
1 USD	¥133.0	¥143.0	¥145.0	¥135.5
1 EUR	¥143.0	¥154.2	¥155.0	¥141.0
1 CNY	¥19.2	¥19.9	¥20.0	¥19.8

● Exchange Rate Sensitivity (Year)

	Net sales	Operating profit
USD	¥0.79 billion	¥0.18 billion
EUR	¥0.58 billion	¥0.14 billion
CNY	¥5.46 billion	¥4.18 billion

Dividend Forecast

- The dividend amount remains unchanged from our initial forecast at the start of the year.

	Interim dividend	Year-end dividend	Total	Payout ratio
Fiscal year ended March 31, 2023	¥40	¥42	¥82	37.5%
Fiscal year ending March 31, 2024 (proposal)	¥42	¥42	¥84	33.8%

Sysmex aims to maintain a proper balance between aggressive investment, which is designed to sustain steady high growth, and returns to our shareholders as our earning power increases. In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 30% under our basic policy of sharing the successes of our operations in line with business performance.

About the Share Split

Objective

To create a more investment-friendly environment and enhance corporate value by lowering the amount per investment unit and improving the liquidity of share.

Method of Share Split

We will conduct a three-for-one split of Sysmex's ordinary share, with a record date of March 31, 2024 (Sunday).

Note: As the record date of March 31, 2024 (Sunday) is a holiday, the record date will effectively be March 29, 2024 (Friday).

Schedule for the Split

- Public notice of record date March 15, 2024 (Friday)
- Record date March 31, 2024 (Sunday)
- Effective date April 1, 2024 (Monday)

Year-End Dividends

The year-end dividend for the fiscal year ending March 31, 2024, which has a record date of March 31, 2024, will be based on the number of shares prior to the stock split.

Note: The Company forecasts a year-end dividend of ¥42 per share.
(This is unchanged from our announcement on May 11, 2023.)

(Appendix)

Quarterly Operating Performance (Q1→Q2→Q3)



The operating margin increased thanks to a substantial improvement in the cost of sales ratio. Although SG&A expenses were affected by inflation, we worked to control R&D and other expenses.

(Billions of yen)

	Q1 (April–June)		Q2 (July–September)		Q3 (October–December)	
	Fiscal year ending March 31, 2024	Ratio	Fiscal year ending March 31, 2024	Ratio	Fiscal year ending March 31, 2024	Ratio
Net sales	95.3	100.0%	117.3	100.0%	113.8	100.0%
Cost of sales	44.9	47.1%	56.7	48.4%	53.0	46.6%
SG&A expenses	30.1	31.6%	32.4	27.6%	33.2	29.2%
R&D expenses	7.1	7.5%	7.8	6.7%	8.2	7.2%
Other income (expenses)	0.1	0.2%	0.2	0.2%	1.0	1.0%
Operating profit	13.2	13.9%	20.5	17.5%	20.3	17.9%
Profit attributable to owners of the parent	8.6	9.0%	13.5	11.6%	12.2	10.8%

Topics (October 2023 to February 2024)



Diagnostics Business

- Sysmex and Fujirebio Holdings, Inc. Enter Tie-up in the Field of Immunoassay and Sign Agreement for the Supply of Reagent Raw Materials (Japan)
- Sysmex Obtains Insurance Coverage for Its Immunoassay Reagent “HISCL M2BPGi™-Qt Assay Kit” for Quantitative Measurement of Hepatic Fibrosis Progression from Blood Samples (Japan)
- Sysmex Makes Megakaryon Corporation into a Subsidiary, Aiming at Accelerating Efforts in the Field of Regenerative and Cellular Medicine (Japan)
- Sysmex and Hitachi High-Tech Corporation Agree to Jointly Develop New Genetic Testing System (Japan)
- Sysmex Expands Sales of Its Reagents for Blood-based Amyloid β Testing to Europe, and accelerates the development of its immunochemistry testing business globally (EMEA)
- Strengthening the Direct Sales and Service System for Business Expansion in Italy (EMEA)
- Sysmex Obtains Regulatory Approval on Three New Models in Order to Expand Local production (China)

Medical Robotics Business

- Regulatory Approval Application Filed for the Use of the hinotori™ Surgical Robot System in Respiratory Surgery (Japan)

Sustainability

- Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Eighth Consecutive Year
- Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fifth Time

XR-Series (Hematology Field) Launch Schedule

- EMEA Launched XR-Series and sample transportation system module (BT-50 etc.) (July 2023)
- Japan Owing to solid results in Q3, sales of hematology instruments were up by double digits (launched in Q2 of the fiscal year ended March 31, 2023).
- AP Launched in Q3 of the fiscal year ending March 31, 2024.
- China BT-50 launched as an additional module for the XN-Series.
Expect to launch the XR-Series in Q4 of the fiscal year ending March 31, 2024.
- Americas BT-50 launched as an additional module for the XN-Series.
Expect to launch the XR-Series in the fiscal year ending March 31, 2025.



View of modules connected to XR-Series

Together for a better
healthcare journey